Haemorrhagic secpticaemia (HS), an acute, fatal and septicaemic disease of cattle and buffalo in tropical regions of Asia and Africa, is considered as major bacterial disease of economical significance with high morbidity and mortality. It is predominantly caused by P. multocida serogroup B:2 strains in India. The disease has been reported from almost all parts of the country despite periodic HS vaccination. In recent times, in order to overcome limitations of conventional vaccines, several highly purified recombinant outer membrane proteins (OMPs) are being evaluated as candidate HS subunit vaccine under alternative strategy. In the present study, the immunogenicity and protective efficacy of three candidate surface antigens (87 kD outer membrane protein [Omp87], VacJ lipoprotein and Transferrin binding protein A [TbpA]) of P. multocida serogroup B:2 were evaluated in mice model. The genes encoding for respective proteins were amplified from P. multocida serogroup B:2 strain P52 (a causative agent of HS), cloned in to pET32a vector, over-expressed in recombinant Escherichia coli as fusion proteins and purified by affinity chromatography. Mice were immunized with recombinant proteins with varying doses along with different adjuvants by subcutaneous route in independent experiments for each protein. The study revealed a significant (P<0.05) rise in antigen specific serum total IgG and subtypes (IgG1 & IgG2a) tires as measured by Indirect-ELISA. Further, challenge studies of immunized mice either with homologous/heterologous strains resulted in variable protective efficacy up to 83.3%. Further, predicted structural characteristics of Omp87, VacJ and TbpA protein by bio-informatic tools were analyzed with respect to generation of protective immunity and future design of vaccine formulations. In conclusion, our findings indicated the immunogenicity and protective efficacy of recombinant OMPs which would likely to assist in selection of candidate antigens in development of composite recombinant HS subunit vaccine along with suitable adjuvants for immunizing susceptible herd.